Scholar Rock gains on FDA approval for first muscle-targeted SMA treatment
14/09/2026 11:41
BUZZ-Scholar Rock gains on FDA approval for first muscle-targeted SMA treatment ** Shares of Scholar Rock SRRK.O rise 10.1% to $61 premarket
** U.S. FDA has approved company's drug Isembyld as the first muscle-targeted treatment for spinal muscular atrophy, a genetic condition that causes worsening muscle weakness
** The nod is for adults and children 2 years and older who are currently receiving therapies that target SMN2, a gene for neurons that control movement
** Commercial launch underway with product available to ship in the coming days - SRRK
** Broad label supports peak sales of $2.3 billion, says brokerage Truist
** Up to last close, shares up 26% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Scholar Rock Holding
See all newsBrief: Scholar Rock Reports New Employee Inducement Grants
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (Maa) To European Medicines Agency (EMA) For Treatment Of Children And Adults With Spinal Muscular Atrophy (SMA)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up